Despite Early Promise GLP-1 Disappoints in Parkinson’s

This post was originally published on Medscape

You will shortly be re-directed to the publisher's website

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD.
Medscape Medical News